CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total revenue	$ 93,459	$ 30,262	$ 25,639
Total cost of revenue	28,187	9,103	9,004
Gross profit	65,272	21,159	16,635
Operating expenses:
Research, development and clinical trials	26,812	22,304	18,831
Selling, general and administrative	69,897	38,283	24,188
Total operating expenses	96,709	60,587	43,019
Loss from operations	(31,437)	(39,428)	(26,384)
Other income (expense):
Interest expense	(3,726)	(3,874)	(3,985)
Other income (expense), net	(1,002)	(877)	1,653
Total other expense, net	(4,728)	(4,751)	(2,332)
Loss before income taxes	(36,165)	(44,179)	(28,716)
Provision for income taxes	(66)	(36)	(32)
Net loss	$ (36,231)	$ (44,215)	$ (28,748)
Net loss per share attributable to common stockholders, basic	$ (1.23)	$ (1.60)	$ (1.16)
Net loss per share attributable to common stockholders, diluted	$ (1.23)	$ (1.60)	$ (1.16)
Weighted average common shares outstanding, basic	29,556,633	27,616,839	24,702,764
Weighted average common shares outstanding, diluted	29,556,633	27,616,839	24,702,764
Net product revenue [Member]
Total revenue	$ 79,234	$ 29,657	$ 25,092
Total cost of revenue	16,970	9,031	8,961
Service Revenue [Member]
Total revenue	14,225	605	547
Total cost of revenue	$ 11,217	$ 72	$ 43